logo

Affimed N.V. (AFMD)



Trade AFMD now with
  Date
  Headline
11/7/2018 7:48:23 AM Affimed Q3 Net Loss EUR 12.0 Mln Or EUR 0.19 Per Share
8/8/2018 7:35:18 AM Affimed Q2 Net Loss EUR 8.0 Mln Or EUR 0.13 Per Share
6/15/2018 5:17:42 AM Affimed Presents New Interim Data From Phase 1b Dose Escalation Study Evaluating AFM13
5/15/2018 7:49:11 AM Affimed Q1 Revenue €0.5 Mln Vs. €0.4 Mln Prior Year
5/3/2018 5:04:39 AM Affimed Announces Official Launch Of Its Redirected Optimized Cell Killing (ROCKTM) Platform
3/20/2018 7:38:49 AM Affimed Q4 Net Loss EUR 6.4 Mln Or EUR 0.14/Shr Vs Loss Of EUR 5.4 Mln Or EUR 0.19/Shr Last Year
3/19/2018 6:04:03 AM Affimed Appoints Leila Alland As Chief Medical Officer, Effective March 26
3/19/2018 6:03:56 AM Affimed Appoints Leila Alland To The Position Of Chief Medical Officer
3/15/2018 4:04:21 AM Affimed To Present Preclinical Data On AFM24 At AACR Annual Meeting 2018
2/13/2018 3:04:07 AM Affimed N.V. Announces Pricing Of Public Offering Of 11.5 Mln Shares At $2.00/shr